First Time Loading...

Horizon Therapeutics PLC
NASDAQ:HZNP

Watchlist Manager
Horizon Therapeutics PLC Logo
Horizon Therapeutics PLC
NASDAQ:HZNP
Watchlist
Price: 116.3 USD
Updated: May 6, 2024
HZNP
/
Income Statement
/
Revenue

Horizon Therapeutics PLC
Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Horizon Therapeutics PLC
Revenue Peer Comparison

Comparables:
ALKS
AMRN
PRTA
M
MURA

Competitive Revenue Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
Horizon Therapeutics PLC
NASDAQ:HZNP
Revenue
$3.6B
CAGR 3-Years
34%
CAGR 5-Years
28%
CAGR 10-Years
60%
Alkermes Plc
NASDAQ:ALKS
Revenue
$1.7B
CAGR 3-Years
17%
CAGR 5-Years
9%
CAGR 10-Years
11%
Amarin Corporation PLC
NASDAQ:AMRN
Revenue
$277.5m
CAGR 3-Years
-23%
CAGR 5-Years
1%
CAGR 10-Years
23%
Prothena Corporation PLC
NASDAQ:PRTA
Revenue
$91.4m
CAGR 3-Years
367%
CAGR 5-Years
147%
CAGR 10-Years
61%
M
Mural Oncology PLC
NASDAQ:MURA
Revenue
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Horizon Therapeutics PLC
Revenue Breakdown

Breakdown by Geography
Horizon Therapeutics PLC

Total Revenue: 3.6B USD
100%
United States: 3.6B USD
98.9%
Non-Us: 39.5m USD
1.1%

Breakdown by Segments
Horizon Therapeutics PLC

Total Revenue: 3.6B USD
100%
Tepezza: 2B USD
54.2%
Krystexxa: 716.2m USD
19.7%
Ravicti: 325.7m USD
9%
Procysbi Developed Technology: 210m USD
5.8%
Uplizna: 154.6m USD
4.3%
Actimmune: 126.1m USD
3.5%
Pennsaid 2%: 73.8m USD
2%
Rayos: 41.9m USD
1.2%
Buphenyl: 7.3m USD
0.2%
Duexis: 4.9m USD
0.1%
Vimovo: 1.9m USD
0.1%
Quinsair: 1.1m USD
0%
Show More
Show Less

See Also

What is Horizon Therapeutics PLC's Revenue?
Revenue
3.6B USD

Based on the financial report for Jun 30, 2023, Horizon Therapeutics PLC's Revenue amounts to 3.6B USD.

What is Horizon Therapeutics PLC's Revenue growth rate?
Revenue CAGR 10Y
60%

Over the last year, the Revenue growth was -4%. The average annual Revenue growth rates for Horizon Therapeutics PLC have been 34% over the past three years , 28% over the past five years , and 60% over the past ten years .

ALPHA SPREAD
Join more than 134,700+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.